Press Releases Featured Image

Press Releases

All Releases

Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation

Blackstone announced the launch of the Blackstone Life Sciences (“Blackstone”) portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug (“IND”) application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications.

Blackstone Announces Plans to Commence a Tender Offer for I’rom Group, One of Japan’s Leading Site Management Organizations, a Mission-Critical Function of Clinical Trials

Blackstone (NYSE:BX) announced today that private equity funds and vehicles managed by Blackstone (“Blackstone”) have entered into a definitive agreement with Toyotaka Mori (“Mr. Mori”), Founder, President & Chief Executive Officer of I’rom Group Co., Ltd. (“I’rom”; TSE stock code 2372), Japan’s leading Site Management Organization (SMO), to jointly take I’rom private. I’rom provides clinical trial management services to pharmaceutical, biotechnology, and medical institutions, and plays a critical role in the success of clinical trials, ensuring that new technologies and medicines are brought to the market efficiently and quickly.

Blackstone Real Estate Completes Privatization of Tricon

Blackstone Remains Committed to Tricon’s Development Platform, including $1 Billion Pipeline of New Single-Family Homes in the U.S. and $2.5 Billion Pipeline of New Apartments in Canada; Plans to Improve Quality of Existing U.S. Single-Family Homes through an Additional $1 Billion of Capital Projects All financial and share price-related information is presented in U.S. dollars […]

Stay up to date